DNAPrint Genomics, Inc. engages in the research and development of genomics-based products and services for biomedical and forensics. The company was founded by Tony N. Frudakis on January 3, 1983 and is headquartered in Sarasota, FL.

Pathway Genomics provides a comprehensive set of genomic testing services across the healthcare spectrum, including tests for general health and wellness, liquid biopsy, pharmacogenomics, hereditary cancer risk and carrier screening. Its general health and wellness tests, including PathwayFit®, Cardiac DNA Insight®, and SkinFit™, equip physicians and patients with genetic information to support lifestyle choices. Liquid biopsy tests, including CancerIntercept™ Detect and Monitor, are non-invasive tests for detection of circulating tumor DNA. Pathway’s pharmacogenomics tests (Mental Health DNA Insight® and Pain Medication DNA Insight®) provide genetic information to help guide selection of optimal medication for management of mental health and pain disorders. Pathway’s hereditary cancer risk tests, including BRCATrue® and ColoTrue®, evaluate genetic factors for future cancer risk. Pathway Genomics Corporation operates a clinical laboratory to provide its commercial genetic testing services to physicians and their patients in the United States and internationally. Pathway Genomics Corporation was incorporated in 2008 and is based in San Diego, California.

AdnaGen AG is a biotechnology company that develops molecular genetic diagnostic testing systems for the medical and clinical research laboratories. The company offers AdnaTest kits including reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics. In addition, it focuses on genetic pre-disposition, pharmoco genetics, and non-invasive prenatal diagnostic systems for early detection, prevention, and monitoring of human diseases. The company was founded in 1999 and is headquartered in Langenhagen, Germany. As of February 23, 2006, AdnaGen AG is a subsidiary of OncoVista, Inc.

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016. The company was founded by Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. It operates through the Pharmaceuticals and Real Estate divisions. The Pharmaceuticals division deals with the manufacture and sale of pharmaceutical products which mainly focus on prescription drugs, infusions, and artificial kidney dialysis solutions. The Real Estate division handles leasing of real estate properties. The company was founded on March 25, 1937 and is headquartered in Osaka, Japan.

Honda Research Institute Europe GmbH, a subsidiary of Honda Motor Co., Ltd., is a company headquartered in Offenbach, Germany. The firm engages in the research and development of information and communication technology in the automotive industry. It was founded in 2003. Bernhard Sendhof, Andreas Richter and Manabu Ozawa are the current co-CEOs of the company.\nThe company says this about itself: In 2003, when the Honda Research Institutes were founded in Japan, in the United States and in Europe, research into computational intelligence, optimization and robotics was our central focus. More than a decade later artificial intelligence is seen as the next big tech thing. We couldn��t agree more. Intelligent systems will shape our future in many ways, ranging from autonomous and accident-free driving to personal robots and from smart design and manufacturing to the efficient use of resources. We envision intelligent systems to work among us, for us and with us. This is why we call it Cooperative Intelligence. The ideas and concepts our researchers introduce on the next pages are the basis for achieving cooperative intelligence.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Fabric Media, Inc. is an American private company located in Los Angeles, CA. The firm operates as a media company. It was founded by Jason Damata, he is currently the CEO of the firm.

Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.

FEI, Inc. is a private company headquartered in the United States. The firm operates commercial land subdividers.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

DakoCytomation is a company highly specialized in systems solutions for diagnostic and research use. Since its beginning in 1966, it has a tradition of being a company where human and caring aspects matter, both within the company and towards its business partners. It is the leading provider of pharmDx™ cancer diagnostic tests.

Suzano Papel e Celulose is a Brazilian company of pulp and paper with presence in over 80 countries. It is the largest pulp and paper company in Latin America. The company is headquartered in Salvador and has offices in Sao Paulo, Buenos Aires, Fort Lauderdale, London, Shanghai and Signy and is one of the largest in its sector in the world.

Sennheiser Electronic Corp. develops and markets headphones, microphones and other professional audio equipment. Its products include wireless and wired microphones, headphones and bluetooth headsets, office speakerphones and parts and accessories. The company was founded in 1991 and is headquartered in Old Lyme, CT.

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

Iverson Genetic Diagnostics provides diagnostic tools to prevent and treat chronic diseases for physicians. It develops genetic tests for disease detection and treatment. The company also provides a warfarin dosing panel that tests for variations in enzymes that can significantly affect warfarin response; and a high-risk HPV panel, a screening test that detects various HPVs. In addition, it offers an MTHFR assay that detects key variants in the metabolism of homocysteine that is associated with coronary artery disease, thrombosis, heart attacks, and strokes. The company was founded in 2006 and is based in Bothell, Washington.

Cronos Therapeutics, Ltd., a biopharmaceutical company, develops therapeutics and diagnostics based on epigenomics for the detection and treatment of cancer. Its GeneICE compounds represent a way of treating diseases by acting to shut down harmful genes and therefore prevent their expression. The company's HyperGenomics platform characterizes disease state by detecting areas on the chromosome where genes are active. Its compound, which is undergoing development, acts to shut down the Bcl-2 gene. Cronos Therapeutics, Ltd. was founded in 2004 and is based in London, the United Kingdom. As of October 3, 2006, Cronos Therapeutics Ltd. is a subsidiary of ValiRX PLC.

Holonic Systems provides medical, IoT, and manufacturing equipment solution services.

Research Development Foundation is an American private company that operates as noncommercial research organizations.